Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW Conjugate Vaccine Booster Study in Adolescents and Adults
NCT02752906Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of meningococcal A conjugate vaccine in meningococcal infection (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W at Day 30. Started Apr 2016; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT02752906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752906.